Technical Analysis for CRGX - CARGO Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Narrow Range Bar | Range Contraction | 2.19% | |
| Down 3 Days in a Row | Weakness | 2.19% | |
| Down 4 Days in a Row | Weakness | 2.19% | |
| Oversold Stochastic | Weakness | 2.19% | |
| Down 3 Days in a Row | Weakness | -0.37% | |
| Oversold Stochastic | Weakness | -0.37% |
| Alert | Time |
|---|---|
| Up 3% | about 11 hours ago |
| Possible Inside Day | about 11 hours ago |
| 60 Minute Opening Range Breakout | about 15 hours ago |
| Up 2% | about 15 hours ago |
| Up 1% | about 15 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/28/2024
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Immune System Tumor Cancer Immunotherapy Gene Therapy Therapies For Cancer T Cells Antigen Cd22 Car T Cell Siglec
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Immune System Tumor Cancer Immunotherapy Gene Therapy Therapies For Cancer T Cells Antigen Cd22 Car T Cell Siglec
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 33.92 |
| 52 Week Low | 13.14 |
| Average Volume | 354,516 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 23.58 |
| 20-Day Moving Average | 20.17 |
| 10-Day Moving Average | 19.14 |
| Average True Range | 1.50 |
| RSI (14) | 34.21 |
| ADX | 20.32 |
| +DI | 12.10 |
| -DI | 19.59 |
| Chandelier Exit (Long, 3 ATRs) | 20.10 |
| Chandelier Exit (Short, 3 ATRs) | 22.75 |
| Upper Bollinger Bands | 22.37 |
| Lower Bollinger Band | 17.96 |
| Percent B (%b) | 0.16 |
| BandWidth | 21.91 |
| MACD Line | -1.47 |
| MACD Signal Line | -1.42 |
| MACD Histogram | -0.0458 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 19.57 | ||||
| Resistance 3 (R3) | 19.53 | 19.20 | 19.42 | ||
| Resistance 2 (R2) | 19.20 | 18.97 | 19.22 | 19.37 | |
| Resistance 1 (R1) | 18.94 | 18.83 | 19.07 | 18.98 | 19.32 |
| Pivot Point | 18.60 | 18.60 | 18.67 | 18.62 | 18.60 |
| Support 1 (S1) | 18.34 | 18.37 | 18.47 | 18.38 | 18.04 |
| Support 2 (S2) | 18.01 | 18.23 | 18.03 | 17.99 | |
| Support 3 (S3) | 17.75 | 18.01 | 17.94 | ||
| Support 4 (S4) | 17.79 |
